Press Releases :: Capricor Therapeutics, Inc. (CAPR)

Capricor Therapeutics, Inc. News: Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

Learn More

Jun 28, 2024 9:00 am EDT

Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy

Jun 25, 2024 8:30 am EDT

Capricor Therapeutics Announces Pre-BLA Meeting with FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Jun 11, 2024 9:25 am EDT

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway

Jun 04, 2024 9:00 am EDT

Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

May 13, 2024 4:05 pm EDT

Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 09, 2024 9:15 am EDT

Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

May 08, 2024 9:00 am EDT

Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences

May 06, 2024 9:00 am EDT

Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13

Apr 24, 2024 9:00 am EDT

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy

Mar 21, 2024 8:30 am EDT

Capricor Therapeutics to Present at Upcoming Investor Conferences

Select a page:

rss_feed News RSS